Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Philip ScheltensMerja HallikainenTimo GrimmerThomas DuningAlida A GouwCharlotte E TeunissenAlle Meije WinkPaul MaruffJohn HarrisonCaroline M van BaalSuzanne BruinsInge LuesNiels D Prins

Published in: Alzheimer's research & therapy (2018)

Clinicaltrials.gov, NCT 02389413 . Registered on 17 March 2015.

Keyphrases

placebo controlled
double blind
phase iii
clinical trial
phase ii
study protocol
phase ii study
cognitive decline
randomized controlled trial
open label